A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo

Starting soon · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Vitiligo

In brief

This is a randomized, double-blind, placebo-controlled Phase Ib/II clinical trial of multiple subcutaneous injections of GR2301 in combination with phototherapy to evaluate the tolerability, safety, pharmacokinetics, and preliminary efficacy in trial participants with vitiligo. The trial will be conducted in two stages: a dose-escalation stage (Phase Ib) and an expansion cohort stage (Phase II).

Key facts

Study ID

NCT07647237

Run by

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

People needed

116

Starts

2026-06-01

Expected to finish

2028-12-01

Last updated by the study team

2026-06-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.